Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) for the reporting period of April 17, 2018, covering an event that occurred on April 12, 2018. The company is a Delaware corporation headquartered in Orlando, Florida.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate governance event regarding employee compensation.
Material Changes
On April 12, 2018, the Board of Directors awarded stock options to all employees and directors based on recent company accomplishments. Key terms of the award include:
- Exercise Price: $0.38 per share (closing price on the award date).
- Vesting Schedule: Three-year vesting period with one-third vesting on each anniversary of issuance.
- Term: Options are exercisable for a 10-year period.
Specific awards to named executive officers were as follows:
- Thomas K. Equels (CEO and President): 125,000 shares.
- Adam Pascale (CFO): 75,000 shares.
- Peter Rodino (Executive Director, Government Relations, General Counsel, & Secretary): 100,000 shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of specific risks and contingencies beyond the standard disclosure of the option grant. The grant was justified by the Board as a reward for "recent accomplishments."
Investor Verification Checklist
- Verify the total number of shares outstanding and the potential dilution impact of the new option grants.
- Confirm the current market price of the stock relative to the $0.38 exercise price to assess the intrinsic value of the awards.
- Review the company's recent financial statements to understand the "recent accomplishments" cited as the basis for the compensation.
- Check for any subsequent filings regarding the vesting conditions or performance metrics attached to these options.